The RASSF1A Tumor Suppressor Activates Bax via MOAP-1

Michele D. Vos(National Institutes of Health), Ashraf Dallol(University of Birmingham), Kristin Eckfeld(National Institutes of Health), Nadia P.C. Allen(National Institutes of Health), Howard Donninger(National Institutes of Health), Luke B. Hesson(University of Birmingham), Diego F. Calvisi(University of Sassari), Farida Latif(University of Birmingham), Geoffrey Clark(National Institutes of Health)
Journal of Biological Chemistry
December 13, 2005
Cited by 142Open Access
Full Text

Abstract

The novel tumor suppressor RASSF1A is frequently inactivated during human tumorigenesis by promoter methylation. RASSF1A may serve as a node in the integration of signaling pathways controlling a range of critical cellular functions including cell cycle, genomic instability, and apoptosis. The mechanism of action of RASSF1A remains under investigation. We now identify a novel pathway connecting RASSF1A to Bax via the Bax binding protein MOAP-1. RASSF1A and MOAP-1 interact directly, and this interaction is enhanced by the presence of activated K-Ras. RASSF1A can activate Bax via MOAP-1. Moreover, activated K-Ras, RASSF1A, and MOAP-1 synergize to induce Bax activation and cell death. Analysis of a tumor-derived point mutant of RASSF1A showed that the mutant was defective for the MOAP-1 interaction and for Bax activation. Moreover, inhibition of RASSF1A by shRNA impaired the ability of K-Ras to activate Bax. Thus, we identify a novel pro-apoptotic pathway linking K-Ras, RASSF1A and Bax that is specifically impaired in some human tumors.


Related Papers

No related papers found

Powered by citation graph analysis